Home Dermatology PDF: Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis
- You cannot add another "PDF: Update on Drugs & Devices: September – October 2019" to your cart. View cart
PDF: Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis
$1.99
PDF Download: Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favourable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods.
Read online:
Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis